Topic: Meaning of ER/PR scores on Oncotype Report

Forum: Diagnosed and Waiting for Test Results — Share with and support others all waiting for test results from CAT scan, PET scan, Oncotype tests, Mammaprint, FISH, IHC, and other diagnostic tests.

Posted on: Mar 30, 2022 08:55PM

Posted on: Mar 30, 2022 08:55PM

odyssey305 wrote:

Hi everyone. Before I call Genomic Health with this, I thought I would check with the wise people on BCO…what is the significance of the ER/PR scores reported on the Oncotype report other than confirming + or - receptor status? Also what is the range for strongly positive, moderately positive etc? I’ve tried to find some information online and came across a similar thread on this board, but I’m still stumped. I’m midway through treatment so this won’t necessarily impact any decisions for me, but I am really curious and maybe others are too as there’s so little information. Thank you!

Dx 12/2021, IDC, Right, 1cm, Stage IB, Grade 1, 1/5 nodes, ER+/PR+, HER2-, FISHISHCISH
Log in to post a reply

Page 1 of 1 (2 results)

Log in to post a reply

Mar 30, 2022 09:06PM moth wrote:

Oncotype uses a different method to determine hormone status than IHC. It is said that if there's a discrepancy, you should go with the IHC. But, in some cases - like mine - it leads to a whole review of IHC status. My 2017 initial IHC from biopsy was 10% faint ER+/PR-/HER2-. Oncotype came back & said I was triple neg. My biopsy sample & my tumor sample did the rounds among pathologists here for 2nd opinions & eventually they coded it as negative as well.

I believe Oncotype factors the strength of the ER positivity into the recurrence score. Not sure how well the search function is doing right now but Beesie did a number of posts about this .. I think she's on board break while the board is being revamped atm

I take weekends off

Initial dx at 50. Seriously?? “Sometimes the future changes quickly and completely and we’re left with only the choice of what to do next." blog: Never Tell Me the Odds

Dx 12/2017, IDC, Left, 1cm, Stage IA, Grade 3, 0/5 nodes, ER-/PR-, HER2- Surgery 12/12/2017 Lumpectomy; Lumpectomy (Left); Lymph node removal Chemotherapy 2/14/2018 AC + T (Taxol) Radiation Therapy 8/13/2018 Whole breast: Breast Dx 2/2020, IDC, Left, Stage IV, metastasized to liver/lungs, Grade 3, ER-/PR-, HER2- Chemotherapy 3/18/2020 Taxol (paclitaxel) Immunotherapy 3/19/2020 Tecentriq (atezolizumab) Chemotherapy 11/26/2020 Abraxane (albumin-bound or nab-paclitaxel) Radiation Therapy 12/9/2020 External Hormonal Therapy 12/16/2020 Femara (letrozole) Radiation Therapy 3/3/2021 External Local Metastases 3/3/2021 Radiation therapy: Bone Targeted Therapy 1/1/2022 Trodelvy (sacituzumab govitecan-hziy) Chemotherapy 6/1/2022 Other
Log in to post a reply

Apr 2, 2022 01:19PM - edited Apr 2, 2022 01:22PM by odyssey305

Hi Moth! That was my next question, about discrepancies - thank you for clearing that up for me. I'm sorry to hear about what you went through, I'm sure all the waiting was nerve-wracking. My initial biopsy report showed that I was strongly ER/PR positive but my Oncotype showed that I was only moderately ER+ and weakly PR+ (if I understood the scores correctly). My MO didn't seem concerned and I didn’ think to ask at the time.Now I'm curious about whether discrepancies are due to tumor heterogeneity or if the Oncotype testing is more sensitive. I'll see if I can pull up Bessie's posts about this…

Hope you have a peaceful weekend😊

Dx 12/2021, IDC, Right, 1cm, Stage IB, Grade 1, 1/5 nodes, ER+/PR+, HER2-, FISHISHCISH

Page 1 of 1 (2 results)

Scroll to top button